Logo
x

Search

Subscribe Now

Idorsia

Idorsia’s Tryvio Receives the US FDA’s Approval for the Treatment of Hypertension

Idorsia’s Tryvio Receives the US FDA’s Approval for the Treatment of Hypertension

  • March 20, 2024
Idorsia Pharmaceuticals Submits NDA to PMDA for Daridorexant to Treat Insomnia

Idorsia Pharmaceuticals Submits NDA to PMDA for Daridorexant to Treat Insomnia

  • October 31, 2023
Idorsia’s Quviviq (daridorexant) Receives NICE Recommendation for Adults with Chronic Insomnia

Idorsia’s Quviviq (daridorexant) Receives NICE Recommendation for Adults with Chronic Insomnia

  • September 18, 2023
Idorsia Reports the Commercial Availability of Quviviq (daridorexant) in Switzerland for Chronic Insomnia Disorder

Idorsia Reports the Commercial Availability of Quviviq (daridorexant) in Switzerland for Chronic Insomnia Disorder

  • June 12, 2023
Idorsia Reports MAA Submission of Aprocitentan to EMA for the Treatment of Resistant Hypertension

Idorsia Reports MAA Submission of Aprocitentan to EMA for the Treatment of Resistant Hypertension

  • January 31, 2023
Idorsia Launches Pivlaz (clazosentan) for the Treatment of Aneurysmal Subarachnoid Hemorrhage in Japan

Idorsia Launches Pivlaz (clazosentan) for the Treatment of Aneurysmal Subarachnoid Hemorrhage in Japan

  • April 20, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.